Phage-associated lytic enzymes for treatment of Bacillus anthracis and related conditions
US8580553B2 · kind B2 · utility
0Cited by
0References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 13, 2008 |
| Grant date | Nov 12, 2013 |
| Priority date | — |
| Expiry date | Aug 29, 2031 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/32
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to methods, compositions and articles of manufacture useful for the treatment of Bacillus anthracis and B. cereus bacteria and spores, and related conditions. The disclosure further relates to methods and compositions for the identification of a phage associated lytic enzyme to rapidly and specifically detect and kill Bacillus anthracis and other bacteria. Related articles of manufacture, methods of degrading spores and methods of treatment of infections or bacteria populations of, or subjects exposed to or at risk for exposure to, Bacillus anthracis are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.